FDA Cleared
New Device
Pathway: 510K
EXG PulseLinQ Cables (EXGPL)
Applicant:
Cb Innovations, LLC
Statutory Profile
Legal Standard:
Substantial Equivalence (SE) to predicate (21 CFR 807)
Product Code:
DSA
Review Panel:
Cardiovascular
21 CFR Regulation:
8
Review Velocity Metrics
Date Received:
2026-08-07
Decision Date:
2026-10-30
Total Review Duration:
84 calendar days (84 days)
Official FDA Research Backlinks
Direct links to primary official records hosted by the U.S. Food and Drug Administration CDRH databases:
Identified Contacts & Correspondents
Oxana Pantchenko
Role: SUBMITTER_CONTACT
Notice a discrepancy or outdated information on this record?
Report to support@fdacleared.org